Aridis Pharmaceuticals (ARDS) News Today Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period June 24, 2024 | globenewswire.comAridis Provides Corporate UpdateMarch 14, 2024 | uk.investing.comAridis Pharmaceuticals Inc (ARDS)February 10, 2024 | bbc.co.ukIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestDecember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024November 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 1, 2023 | morningstar.comAridis Pharmaceuticals Inc ARDSOctober 22, 2023 | benzinga.comAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsOctober 21, 2023 | msn.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 20, 2023 | markets.businessinsider.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationSeptember 15, 2023 | finance.yahoo.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAugust 21, 2023 | investing.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 2, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2 Million OfferingJuly 18, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 17, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301July 13, 2023 | finance.yahoo.comAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301July 12, 2023 | finance.yahoo.comAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationJune 22, 2023 | marketwatch.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 20, 2023 | finance.yahoo.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 9, 2023 | finanznachrichten.deAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 8, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 1, 2023 | benzinga.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastMay 31, 2023 | finance.yahoo.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignMay 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QApril 26, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KApril 3, 2023 | bizjournals.comBig pharma, small drug maker spar over pneumonia drug dealMarch 31, 2023 | finance.yahoo.comAridis Provides Corporate UpdateMarch 29, 2023 | msn.comAstraZeneca Axes Pneumonia Drug Pact With AridisMarch 14, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are DivingMarch 14, 2023 | marketwatch.comAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSMarch 14, 2023 | msn.comAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets GoalsMarch 14, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockMarch 13, 2023 | msn.comAridis Skyrockets on Impressive Data In Cystic FibrosisMarch 13, 2023 | msn.comAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyMarch 13, 2023 | finance.yahoo.comWhy Aridis Pharmaceuticals Shares Are Soaring TodayMarch 13, 2023 | marketwatch.comAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSMarch 13, 2023 | finance.yahoo.comAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsFebruary 17, 2023 | finanznachrichten.deInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money ReportFebruary 15, 2023 | finance.yahoo.comWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?February 6, 2023 | finance.yahoo.comIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay AreaFebruary 1, 2023 | finance.yahoo.comHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock NowJanuary 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)January 26, 2023 | msn.comAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniaJanuary 25, 2023 | finance.yahoo.comAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)January 25, 2023 | marketbeat.comTrading was temporarily halted for "ARDS" at 04:01 PM with a stated reason of "News pending."January 24, 2023 | marketbeat.comTrading was temporarily halted for "ARDS" at 11:01 AM with a stated reason of "LULD pause."January 17, 2023 | finance.yahoo.comNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateDecember 28, 2022 | finance.yahoo.comAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25December 12, 2022 | finance.yahoo.com(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… ARDS Media Mentions By Week ARDS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.000.62▲Average Medical News Sentiment ARDS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼00▲ARDS Articles Average Week Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMNN News MNPR News GHSI News AVTX News KPRX News LUMO News CMMB News NRSN News MIRA News RDHL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.